StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Stoke Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Stoke Therapeutics's total assets was $393.97M at Jun 30, 2026. For fiscal 2025 it was $418.43M, up 54.1% from the year before. The highest annual figure on record is $418.43M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$418.43M+54.1%
FY2024Dec 31, 2024$271.56M+18.9%
FY2023Dec 31, 2023$228.34M-10.8%
FY2022Dec 31, 2022$256.07M+7.2%
FY2021Dec 31, 2021$238.87M-19.8%
FY2020Dec 31, 2020$297.93M+30.2%
FY2019Dec 31, 2019$228.75M+112.7%
FY2018Dec 31, 2018$107.54M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$393.97M+2.5%
Q1 FY2026Mar 31, 2026$443.28M+8.9%
Q4 FY2025Dec 31, 2025$418.43M+54.1%
Q3 FY2025Sep 30, 2025$360.26M+22.8%
Q2 FY2025Jun 30, 2025$384.51M+24.9%
Q1 FY2025Mar 31, 2025$406.89M+98.3%
Q4 FY2024Dec 31, 2024$271.56M+18.9%
Q3 FY2024Sep 30, 2024$293.32M+22.3%
Q2 FY2024Jun 30, 2024$307.76M+19.8%
Q1 FY2024Mar 31, 2024$205.18M-27.2%
Q4 FY2023Dec 31, 2023$228.34M-10.8%
Q3 FY2023Sep 30, 2023$239.89M-13.6%
Q2 FY2023Jun 30, 2023$256.92M-14.8%
Q1 FY2023Mar 31, 2023$281.80M-10.8%
Q4 FY2022Dec 31, 2022$256.07M+7.2%
Q3 FY2022Sep 30, 2022$277.63M+9.4%
Q2 FY2022Jun 30, 2022$301.43M+14.0%
Q1 FY2022Mar 31, 2022$315.94M+13.3%
Q4 FY2021Dec 31, 2021$238.87M-19.8%
Q3 FY2021Sep 30, 2021$253.77M+26.9%
Q2 FY2021Jun 30, 2021$264.45M+25.8%
Q1 FY2021Mar 31, 2021$278.91M+26.3%
Q4 FY2020Dec 31, 2020$297.93M+30.2%
Q3 FY2020Sep 30, 2020$199.94M-16.3%
Q2 FY2020Jun 30, 2020$210.21M-14.7%
Q1 FY2020Mar 31, 2020$220.84M+105.4%
Q4 FY2019Dec 31, 2019$228.75M–
Q3 FY2019Sep 30, 2019$238.83M–
Q2 FY2019Jun 30, 2019$246.37M–
Q4 FY2018Dec 31, 2018$107.54M–

More Stoke Therapeutics figures

See a number that looks wrong?